Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model FcγRIIA and FcαRI

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jun 28

PMID 34177967

Citations 14

Authors

Fabian Bohlander

Dennis Riehl

Sabrina Weissmuller

Marcus Gutscher

Jorg Schuttrumpf

Stefanie Faust

Affiliations

Soon will be listed here.

Abstract

The rapid spread of SARS-CoV-2 has induced a global pandemic. Severe forms of COVID-19 are characterized by dysregulated immune response and "cytokine storm". The role of IgG and IgM antibodies in COVID-19 pathology is reasonably well studied, whereas IgA is neglected. To improve clinical outcome of patients, immune modulatory drugs appear to be beneficial. Such drugs include intravenous immunoglobulin preparations, which were successfully tested in severe COVID-19 patients. Here we established a versatile model to study inflammatory as well as anti-inflammatory processes by therapeutic human immunoglobulins. We dissect the inflammatory activation on neutrophil-like HL60 cells, using an immune complex consisting of latex beads coated with spike protein of SARS-CoV-2 and opsonized with specific immunoglobulins from convalescent plasma. Our data clarifies the role of Fc-receptor-dependent phagocytosis IgA-FcαRI and IgG-FcγR for COVID-19 disease followed by cytokine release. We show that COVID-19 associated inflammation could be reduced by addition of human immunoglobulin preparations (IVIG and trimodulin), while trimodulin elicits stronger immune modulation by more powerful ITAMi signaling. Besides IgG, the IgA component of trimodulin in particular, is of functional relevance for immune modulation in this assay setup, highlighting the need to study IgA mediated immune response.

Citing Articles

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID).

Agafina A, Aguiar V, Rossovskaya M, Fartoukh M, Hajjar L, Thiery G Eur J Med Res. 2024; 29(1):418.

PMID: 39138518 PMC: 11321023. DOI: 10.1186/s40001-024-02008-x.

Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval.

Choi H, Choi A, Kopp J, Winkler C, Cho S J Korean Med Sci. 2024; 39(14):e134.

PMID: 38622939 PMC: 11018982. DOI: 10.3346/jkms.2024.39.e134.

Multifaceted Tissue-Protective Functions of Polyvalent Immunoglobulin Preparations in Severe Infections-Interactions with Neutrophils, Complement, and Coagulation Pathways.

Schmidt C, Weissmuller S, Heinz C Biomedicines. 2023; 11(11).

PMID: 38002022 PMC: 10669904. DOI: 10.3390/biomedicines11113022.

The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial.

Singer M, Torres A, Heinz C, Weissmuller S, Staus A, Kistner S Crit Care. 2023; 27(1):436.

PMID: 37946226 PMC: 10634136. DOI: 10.1186/s13054-023-04719-9.

Transcriptome-based analysis of human peripheral blood reveals regulators of immune response in different viral infections.

Ivanov S, Tarasova O, Poroikov V Front Immunol. 2023; 14:1199482.

PMID: 37795081 PMC: 10546413. DOI: 10.3389/fimmu.2023.1199482.

References

Orth-Holler D, Eigentler A, Stiasny K, Weseslindtner L, Most J . Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection. J Infect. 2020; 82(2):282-327. PMC: 7501147. DOI: 10.1016/j.jinf.2020.09.015. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S . Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. J Clin Med. 2020; 9(10). PMC: 7600936. DOI: 10.3390/jcm9103188. View

Kakoullis L, Pantzaris N, Platanaki C, Lagadinou M, Papachristodoulou E, Velissaris D . The use of IgM-enriched immunoglobulin in adult patients with sepsis. J Crit Care. 2018; 47:30-35. DOI: 10.1016/j.jcrc.2018.06.005. View

Paces J, Strizova Z, Smrz D, cerny J . COVID-19 and the immune system. Physiol Res. 2020; 69(3):379-388. PMC: 8648321. DOI: 10.33549/physiolres.934492. View

Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y . Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56(2). PMC: 7236821. DOI: 10.1183/13993003.01526-2020. View

Kubagawa H, Skopnik C, Zimmermann J, Durek P, Chang H, Yoo E . Authentic IgM Fc Receptor (FcμR). Curr Top Microbiol Immunol. 2017; 408:25-45. DOI: 10.1007/82_2017_23. View

Schwaiger J, Karbiener M, Aberham C, Farcet M, Kreil T . No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic. J Infect Dis. 2020; 222(12):1960-1964. PMC: 7546122. DOI: 10.1093/infdis/jiaa593. View

Lauw F, Pajkrt D, Hack C, Kurimoto M, van Deventer S, van der Poll T . Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000; 165(5):2783-9. DOI: 10.4049/jimmunol.165.5.2783. View

10.

Trayner I, Bustorff T, Etches A, Mufti G, Foss Y, Farzaneh F . Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res. 1998; 22(6):537-47. DOI: 10.1016/s0145-2126(98)00041-1. View

11.

Heineke M, van Egmond M . Immunoglobulin A: magic bullet or Trojan horse?. Eur J Clin Invest. 2016; 47(2):184-192. DOI: 10.1111/eci.12716. View

12.

Huang Z, Chen H, Xue M, Huang H, Zheng P, Luo W . Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19. Clin Exp Immunol. 2020; 202(2):210-219. PMC: 7405228. DOI: 10.1111/cei.13500. View

13.

Lin L, Lu L, Cao W, Li T . Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. PMC: 7170333. DOI: 10.1080/22221751.2020.1746199. View

14.

Wang J, Li Q, Yin Y, Zhang Y, Cao Y, Lin X . Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19. Front Immunol. 2020; 11:2063. PMC: 7461898. DOI: 10.3389/fimmu.2020.02063. View

15.

Gelfand E . Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012; 367(21):2015-25. DOI: 10.1056/NEJMra1009433. View

16.

Langereis J, van der Flier M, de Jonge M . Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections. Front Immunol. 2018; 9:1925. PMC: 6115500. DOI: 10.3389/fimmu.2018.01925. View

17.

Scoppetta C, Di Gennaro G, Polverino F . Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020; 24(9):5178-5179. DOI: 10.26355/eurrev_202005_21214. View

18.

Wagar L, DiFazio R, Davis M . Advanced model systems and tools for basic and translational human immunology. Genome Med. 2018; 10(1):73. PMC: 6162943. DOI: 10.1186/s13073-018-0584-8. View

19.

Bakema J, van Egmond M . The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 2011; 4(6):612-24. DOI: 10.1038/mi.2011.36. View

20.

Fu Y, Cheng Y, Wu Y . Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020; 35(3):266-271. PMC: 7090474. DOI: 10.1007/s12250-020-00207-4. View